Canadian Association of Gastroenterology position statement: Fecal microbiota transplant therapy

Canadian Journal of Gastroenterology and Hepatology

Volumn 28, Issue 2, 2014, Pages 66-68

  Moayyedi, Paul ^a   Marshall, JohnK ^a   Yuan, Yuhong ^a   Hunt, Richard ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

FIDAXOMICIN; METRONIDAZOLE; PROTON PUMP INHIBITOR; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; CLOSTRIDIUM DIFFICILE INFECTION; FECAL MICROBIOTA TRANSPLANT THERAPY; FECES MICROFLORA; GASTROENTEROLOGY; HUMAN; INFLAMMATORY BOWEL DISEASE; MEDICAL SOCIETY; META ANALYSIS (TOPIC); MICROBIOME; NOTE; PATIENT SAFETY; PRION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW (TOPIC); TRANSPLANTATION;

CANADA; FECES; GASTROENTEROLOGY; HUMANS; MICROBIOTA; SOCIETIES, MEDICAL; TRANSPLANTATION;

EID: 84904264732     PISSN: 22912789     EISSN: 22912797     Source Type: Journal    
DOI: 10.1155/2014/346590     Document Type: Note

References (34)

1. Zhang F, Luo W, Shi Y, et al. Should we standardize the 1700-year-old fecal microbiota transplantation? Am J Gastroenterol 2012;107:1755.
2. Krever H. Commission of Inquiry on the Blood System in Canada. Government of Canada Publications 1997 ISBN 0-660-17230-5.
3. El-Matary W. Fecal microbiota transplantation: Long-term safety issues. Am J Gastroenterol 2013;108:1537-8.
4. Kassam Z, Lee CH, Yuan Y, Hunt RH. Navigating long-term safety in fecal microbiota transplantation. Am J Gastroenterol 2013;108:1538.
5. Cheng J, Palva AM, de Vos WM, Satokari R. Contribution of the intestinal microbiota to human health: From birth to 100 years of age. Curr Topics Microbiol Immunol 2013;358:323-46.
6. Dial S, Delaney JAC, Barkun AN, Suissa S. Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease. JAMA 2005;294:2989-95. (Pubitemid 41817660)
7. Bassetti M, Villa G, Pecori D, Arzese A, Wilcox M. Epidemiology, diagnosis and treatment of Clostridium difficile infection. Exp Rev Antiinfect Ther 2012;10:1405-23.
8. Janarthanan S, Ditah I, Phil M, et al. Clostridium difficile-associated diarrhea and proton pump inhibitor therapy: A meta-analysis. Am J Gastroentrol 2012;107:1001-10.
9. Kwok CS, Arthur AK, Anibueze CI, et al. Risk of Clostridium difficile infection with acid suppressing drugs and antibiotics: Meta-analysis. Am J Gastroenterol 2012;107:1011-9.
10. Leontiadis GI, Miller MA, Howden CW. How much do PPIs contribute to C. difficile infections? Am J Gastroenterol 2012;107:1020-1.
11. Lamontagne F, Labbe AC, Haeck O, et al. Impact of emergency colectomy on survival of patients with fulminant Clostridium difficile colitis during an epidemic caused by a hypervirulent strain. Ann Surg 2007;245:267-72. (Pubitemid 46148486)
12. Surawicz CM, Brandt LJ, Binion DG, et al. Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. Am J Gastroenterol 2013;108:478-98.
13. Bakken JS. Fecal bacteriotherapy for recurrent Clostridium difficile infection. Anaerobe 2009;15:285-9.
14. McFarland LV, Elmer GW, Surawicz CM. Breaking the cycle: Treatment strategies for 163 cases of recurrent Clostridium difficile disease. Am J Gastroenterol 2002;97:1769-75. (Pubitemid 34761404)
15. Cornely OA, Crook DW, Esposito R, et al. Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: A double-blind, non-inferiority, randomised controlled trial. Lancet Infect Dis 2012;12:281-9.
16. Borody TJ, Warren EF, Leis SM, et al. Bacteriotherapy using fecal flora: Toying with human motions. J Clin Gastroenterol 2004;38:475-83. (Pubitemid 38808419)
17. Kassam Z, Lee CH, Yuan Y, Hunt RH. Fecal microbiota transplantation for Clostridium difficile infection: Systematic review and meta-analysis. Am J Gastroenterol 2013;108:500-8.
18. Brandt LJ, Aroniadis OC, Mellow M, et al. Long-term follow-up of colonoscopic fecal microbiota transplant for recurrent Clostridium difficile infection. Am J Gastroenterol 2012;107:1079-87.
19. Jorup-Ronstrom C, Hakanson A, Sandell S, et al. Fecal transplant against relapsing Clostridium difficile-associated diarrhea in 32 patients. Scand J Gastroenterol 2012;47:548-52.
20. Hamilton MJ, Weingarden AR, Sadowsky MJ, Khoruts A. Standardized frozen preparation for transplantation of fecal microbiota for recurrent Clostridium difficile infection. Am J Gastroenterol 2012;107:761-7.
21. Rubin TA, Gessert CE, Aas J, Bakken JS. Fecal microbiome transplantation for recurrent Clostridium difficile infection: Report on a case series. Anaerobe 2013;19:22-6.
22. Patel NC, Griesbach CL, DiBaise JK, Orenstein R. Fecal microbiota transplant for recurrent Clostridium difficile infection: Mayo clinic in Arizona experience. Mayo Clinic Proc 2013;88:799-805.
23. Van Nood E, Vrieze A, Nieuwdorp M, et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Eng J Med 2013;368:407-15.
24. Damman CJ, Miller SI, Surawicz CM, Zisman TL. The microbiome and inflammatory bowel disease: Is there a role for fecal microbiota transplantation? Am J Gastroenterol 2012;107:1452-9.
25. Bennet JD, Brinkman M. Treatment of ulcerative colitis by implantation of normal colonic flora. Lancet 1989;1:164. (Pubitemid 19034066)
26. Borody TJ, Warren EF, Leis S, Surace R, Ashman O. Treatment of ulcerative colitis using fecal bacteriotherapy. J Clin Gastroenterol 2003;37:42-7. (Pubitemid 36734332)
27. Angelberger S, Reinisch W, Makrislathis A, et al. Temporal bacterial community dynamics vary among ulcerative patients after fecal microbiota transplantation. Am J Gastroenterol 2013;108:1620-30.
28. Kump PK, Grochenig HP, Lackner S, et al. Alteration of intestinal dysbiosis by fecal microbiota transplantation does not induce remission in patients with chronic active ulcerative colitis. Inflamm Bowel Dis 2013;19:2155-65.
29. Kunde S, Pham A, Bonczyk S, et al. Safety, tolerability and clinical response after fecal transplantation in children and young adults with ulcerative colitis. J Pediatr Gastroenterol Nutr 2013;56:597-601.
30. Schwartz M, Gluck M, Koon S. Norovirus gastroenteritis after fecal microbiota transplantation for treatment of Clostridium difficile infection despite asymptomatic donors and lack of sick contacts. Am J Gastroenterol 2013;108:1367.
31. Brandt LJ. FMT: First step in a long journey. Am J Gastroenterol 2013;108:1367-8.
32. Bakken JS, Borody T, Brandt LJ, et al. Treating Clostridium difficile with fecal microbiota transplantation. Clin Gastroenterol Hepatol 2011;9:1044-9.
33. Allen-Vercoe E, Reid G, et al. A Canadian Working Group report on fecal microbial therapy: Microbial ecosystems therapeutics. Can J Gastroenterol 2012;26:457-62.
34. Brandt LJ. American Journal of Gastroenterology Lecture: Intestinal microbiota and the role of fecal microbiota transplant (FMT) in treatment of C. difficile infection. Am J Gastroenterol 2013;108:177-85.